Focused On-demand Library for Cyclic AMP-dependent transcription factor ATF-1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Activating transcription factor 1; Protein TREB36

Alternative UPACC:

P18846; B4DRF9; P25168; Q9H4A8


Cyclic AMP-dependent transcription factor ATF-1, also known as Activating transcription factor 1 and Protein TREB36, plays a pivotal role in cellular processes. It binds the cAMP response element (CRE), a sequence found in many viral and cellular promoters, and the Tax-responsive element (TRE) of HTLV-I. ATF-1 is crucial in mediating PKA-induced stimulation of CRE-reporter genes and represses the expression of FTH1 and other antioxidant detoxification genes, thereby triggering cell proliferation and transformation.

Therapeutic significance:

Angiomatoid fibrous histiocytoma, a distinct variant of malignant fibrous histiocytoma, is associated with ATF-1. Chromosomal aberrations involving ATF1, such as translocations with FUS and EWSR1, result in chimeric proteins linked to the disease. Understanding the role of ATF-1 could open doors to potential therapeutic strategies for this and related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.